Intervention not reported
Adverse events (flap‐complications) · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Inattention Measured using SNAP‐IV inattention subscale (range 0 to 27) · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impulsivity · Children aged 6 to 18 years with ASD
2 findings from 1 review
Hyperactivity · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impaired social interaction · Children aged 6 to 18 years with ASD
2 findings from 1 review
Impaired communication · Children aged 6 to 18 years with ASD
2 findings from 1 review
Stereotypical behaviours · Children aged 6 to 18 years with ASD
2 findings from 1 review
Overall ASD · Children aged 6 to 18 years with ASD
2 findings from 1 review
Total number of adverse events · Children aged 6 to 18 years with ASD
2 findings from 1 review
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in recurrent venous thromboembolism compared with standard therapy (moderate certainty).
1 finding from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
Idrabiotaparinux showed no clear difference in all‐cause mortality compared with idraparinux (low certainty).
1 finding from 1 review
Heparin‐induced thrombocytopenia ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether idrabiotaparinux changes all harmful effects compared with idraparinux (very low certainty).
1 finding from 1 review
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
It is very uncertain whether low molecular weight heparin and idraparinux changes recurrent venous thromboembolism compared with standard therapy (very low certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
2 findings from 1 review
All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Heparin‐induced thrombocytopaenia · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent venous thromboembolism · people > 18 years of age with a diagnosed deep vein thrombosis
Idraparinux showed no clear difference in recurrent venous thromboembolism compared with standard therapy (low certainty).
1 finding from 1 review
Major bleeding · people > 18 years of age with a diagnosed deep vein thrombosis
Fondaparinux plus vitamin K antagonist showed no clear difference in major bleeding during the initial treatment compared with standard therapy (moderate certainty).
2 findings from 1 review